European Authorities Recommend Approval Of Wegovy For Obesity

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the authorization of Novo Nordisk A/S's NVO Wegovy for chronic weight management in adults with obesity.
Wegovy is a once-weekly semaglutide 2.4 mg injection.
The positive CHMP opinion is based on the STEP phase 3a trial program results that showed an average weight loss of 17-18% sustained over 68 weeks.
Wegovy demonstrated a safe and well-tolerated profile across the program, with the most common adverse events being gastrointestinal.
Novo Nordisk expects to receive final marketing authorization from the European Commission in approximately two months.
In September 2021, Wegovy was approved by the U.K. Medicines and Health products Regulations Agency (MHRA).
Novo Nordisk expects to launch Wegovy in Europe in 2H of 2022.
Related Link: Novo Nordisk's Semaglutide Gets FDA Approval to Tackle Obesity.
Price Action: NVO shares are up 0.59% at $113.37 during the market session on the last check Thursday.